Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... issued its first compulsory licence in May 2007, for Merck Sharp & Dohme's Stocrin (efavirenz). Rising patient numbers, increasing resistance levels, rising costs and high-risk ...
2009 NOV 1 ... and 96-week efficacy and safety data from the ongoing Phase 3 MERIT (Maraviroc versus Efavirenz Regimens as Initial Therapy) trial and MERIT ES (analysis of the MERIT study with the ...
2009 NOV 16 ... receiving a rifampin (rifampicin)-containing regimen were initiated on treatment with efavirenz at 600 mg/day plus stavudine-lamivudine. Fasting...
2009 NOV 16 ... combination with Truvada (emtricitabine/tenofovir disoproxil fumarate) or Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate). The recommended dose for the ...
2009 NOV 2 ... by Gilead's antiviral franchise, including the strong growth in sales of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) and continued growth ...
2009 NOV 9 ... 338 (90.8%) patients had previously received stavudine and/or zidovudine + lamivudine + efavirenz or nevirapine; 41 of 338 (12.1%) had received tenofovir (TDF). The most common ...
2009 NOV 9 ... the pharmacokinetics of etravirine once and twice daily without and with a preceding efavirenz intake period in healthy volunteers. Volunteers were randomized to receive etravirine ...
2009 OCT 19 ... "The non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) is directly conjugated by the UDP-glucuronosyltransferase (UGT) pathway to form ...
2009 NOV 16 ... by revelations of a specific CYP2B6 genotype significantly affecting the metabolism of efavirenz, an anti-HIV type-1 agent," investigators in Toyama, Japan report. "The ...
2009 NOV 9 ... virologic suppression was finally achieved with a combination of lamivudine, abacavir, efavirenz, and lopinavir/ritonavir." Dinavahi and colleagues published their study ...
2009 NOV 1 ... A new study, 'Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and ...
2009 OCT 12 ... between the different genotypes. The proposed method was applied to data from an HIV-1 Efavirenz clinical trial study. The obtained model revealed the direction of evolution over time ...
2009 NOV 9 ... Syndromes, researchers in Netherlands conducted a study "To establish whether efavirenz dose reduction in patients with high plasma concentrations prevents toxicity-induced ...
2009 NOV 9 ... "934 was an open-label, randomized Phase III study of emtricitabine + tenofovir DF + efavirenz (FTC + TDF + EFV) compared with lamivudine + zidovudine +...
2009 NOV 23 ... virological response to ETV varied among algorithms in patients with exposure to efavirenz (EFV)/nevirapine (NVP), ranging from 3.8% (95% CI 2.5-5.6%) for ANRS to 56.2% (95% CI ...
